Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance.

Cancer letters - 28 Dec 2016

Bu Yiwen, Cai Guoshuai, Shen Yi, Huang Chenfei, Zeng Xi, Cao Yu, Cai Chuan, Wang Yuhong, Huang Dan, Liao Duan-Fang, Cao Deliang

Abstract excerpt

Inactivation of p53 occurs frequently in various cancers. RITA is a promising anticancer small molecule that dissociates p53-MDM2 interaction, reactivates p53 and induces exclusive apoptosis in cancer cells, but acquired RITA resistance remains a major drawback. This study found that the site-differential phosphorylation of nuclear factor-κB (NF-κB) RelA/p65 creates a barcode for RITA chemosensitivity in cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple
Share to Furans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HCT116 Cells

Share to MCF-7 Cells

Share to Multidrug Resistance-Associated Proteins

Share to Transcription Factor RelA

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 27721021
DOI: 10.1016/j.canlet.2016.10.006

Genes

ABCC6
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance.PMID 27721021Read ↗

A phosphomimetic mutant of RelA/p65 at Ser536 induces apoptosis and senescence: An implication for tumor-suppressive role of Ser536 phosphorylation.Semantic proximity Read ↗

Targeting Nuclear Factor-Kappa B to Overcome Resistance to ChemotherapySemantic proximity Read ↗

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancerSemantic proximity Read ↗

Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.Semantic proximity Read ↗

Trans-(±)-kusunokinin alters EMT markers and inhibits lung cancer cells by hindering polyol pathwaySemantic proximity Read ↗

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.Semantic proximity Read ↗

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Transcription Factors and Methods for the Pharmacological Correction of Their ActivitySemantic proximity Read ↗

RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma.Semantic proximity Read ↗

Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of ViewSemantic proximity Read ↗

IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in CancerSemantic proximity Read ↗

Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.